Skip to content

D-Limonene Intervention Studies on Health

D-Limonene Intervention Studies on Health

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030200
Enrollment
Unknown
Registered
2020-02-25
Start date
2020-03-01
Completion date
Unknown
Last updated
2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers, population at high risk of lung cancer, pulmonary nodules

Interventions

Intervention group:Lemon powder
Control group:Placebo

Sponsors

Tongren Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Stage A: 1. Healthy subjects aged >=18 years; 2. BMI > 18.5kg / m2; 3. No history of allergies to citrus fruits; 4. Voluntarily participate and sign the informed consent; Stage B additonally includes the following criteria: 1. 6 months or more in BBQ service and at least 4 days a week in the workplace. Stage C additionally includes the following inclusion criteria: 1. Aged >= 40 years. 2. Meet the diagnostic criteria of small pulmonary nodules, with a diameter of 10 mm or less.

Exclusion criteria

Exclusion criteria: 1. Patients with acute or chronic gastrointestinal diseases, including acute gastritis, chronic gastritis, peptic ulcer, acute enteritis, chronic enteritis, irritable bowel syndrome, etc. 2. Consumed more than 500g/d of citrus food in the past week (fruit juice, lemon, citrus peel, grapefruit tea, etc). 3. Complicated with serious diseases such as heart, liver, kidney or hematopoietic system. 4. Pregnant or breast-feeding women, women of child-bearing potential who do not use adequate contraception. 6. Taking anti-inflammatory drugs or antioxidant supplements (such as vitamin C or vitamin E). 7. Those with surgery arrangements in the next 3 months. 8. Participated in another clinical trial within the past 3 months. 9. There are other serious diseases that researchers consider unsuitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
Intervention implementation compliance rate (Stage A);Urine S-phenylthioglycolic acid (SPMA) level (Stage B);Serum miR-195 expression level (Stage C);

Secondary

MeasureTime frame
Inflammation markers;Metabolites;Pulmonary function;Control rate of pulmonary nodules;Oxidative stress markers;Urinary metabolomics;Safety indicators;

Countries

China

Contacts

Public ContactBiyun Qian

Tongren Hospital, Shanghai Jiaotong University School of Medicine

qianbiyun@126.com+86 13818741695

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026